This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.


Clinical Programs

Maurer et al; EAACI, July 2021
"The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria"
 Read More →

Maurer et al; EAACI, June 2020
"CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study"
 Read More →

Seibel et al; ACAAI, November 2019
"CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases"
 Read More →

Sanborn et al; SITC 2020 Poster, November 2020
"
CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)"
PDF Read More →

Sanborn et al; SITC 2019 Poster, November 2019
"Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers"
PDF Read More →

Sanborn et al; AACR 2019 Poster, April 2019
"First-in-human Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results"
PDF Read More →

Sanborn et al; SITC 2018 Poster, November 2018
"Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140"
PDF Read More →

Thomas et al; AACR 2018 Poster, April 2018
"Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models"
PDF Read More →

Thomas et al; Society for Immunotherapy of Cancer, November 2017
"Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy"
PDF Read More →

He et al; ASH 2016 Poster, December 2016
"CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity"
PDF Read More →

Vitale et al; SITC 2016 Poster, November 2016
“Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy”
PDF Read More →

Vitale et al; AACR 2016 Poster, April 2016
“Development and characterization of novel CD40 antibody agonists for cancer immunotherapy”
PDF Read More →

Sanborn et al; ASCO 2021 Poster, June 2021
"A Phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
PDFRead More →

Yellin et al; SITC 2020 Poster, November 2020
"CDX527-01, a Phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
PDFRead More →

Vitale et al; Cancer Immunology, Immunotherapy, May 2020
"Development of CDX‑527: a bispecific antibody combining PD‑1 blockade and CD27 costimulation for cancer immunotherapy"
PDFRead More 

Vitale et al; SITC 2019 Poster, November 2019
"
Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies"
PDFRead More 

Vitale et al; AACR 2019 Poster, April 2019
"CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1"
PDFRead More 

Vitale et al; AACR 2018 Poster, April 2018
"Development of novel bispecific immune modulating antibodies"
PDFRead More →

Thomas et al; AACR 2019 Presentation, April 2019
"Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA"
PDF Read More →

Ohri et al; AACR 2018 Presentation, April 2018
"FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer"
PDF Read More →

Marron et al; AACR 2016 Poster, April 2016
"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"
PDF Read More →

Jaglowski et al; ASBMT 2016 Poster, February 2016
"Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"
PDF Read More →

Anandasabapathy et al; Bone Marrow Transplantation, April 2015
“Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers”
Read More →

Yellin et al; BMT 2013 Presentation, February 2013
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”  
PDF Read More →

Anandasabapathy et al; ASH 2012 Poster, December 2012
“A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers”
PDF Read More →

Wasiuk et al; AACR Immune Cell Therapies for Cancer 2019 Poster; August 2019
"Conditioning Treatment with a CD27 Antibody Enhances in vivo Expansion and Antitumor Activity of Adoptively Transferred T Cells"
PDFRead More 

Reardon et al; SNO 2018; November 2018 
“Anti-CD27 agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma: Phase 2 Clinical Trial Results”
PDF Read more → 

Sanborn et al; ASCO 2017; June 2017
“Clinical Results with Combination of Anti-CD27 Agonist Antibody, Varlilumab, with Anti-PD1 Antibody, Nivolumab, in Advanced Cancer Patients”
PDF Read more → 

Burris et al; Journal of Clinical Oncology; May 2017
“Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors”
Read More →

Sanborn et al; AACR 2016 Poster; April 2016
"Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"
PDF Read more → 

He et al; SITC 2015 Poster; November 2015
"The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"
PDF Read more → 

Ramakrishna et al; Journal for ImmunoTherapy of Cancer; August 2015
"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"
PDF Read more → PDF Supplemental data →

Thomas et al; AACR 2015 Poster; April 2015
"Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site "
PDF Read more →

Bullock et al; SITC 2014 Poster, November 2014
“Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity”
PDF Read More →

Infante et al; ASCO 2014 Poster, June 2014
“Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors”
PDF Read More →

Ansell et al; ASCO 2014 Poster, June 2014
“Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies”
PDF Read More →

Thomas et al; OncoImmunology, January 2014
“Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity”
PDF Read More →

Keler et al; SITC 2013 Poster, November 2013
“Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models”
PDF Read More →

Burris, et al; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

Ansell, Stephen; SITC 2013 Poster, November 2013
“A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors”
PDF Read More →

He et al; Journal of Immunology, September 2013
“Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice
PDF Read More →

Sundarapandiyan et al; AACR 2013 Poster, April 2013
“Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb”
PDF Read More →

Vitale et al; Clinical Cancer Research, May 2012
“Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia”
Read More →

He et al; AACR 2012 Poster, April 2012
“Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model”
PDF Read More →

He et al; ASH 2011 Poster, December 2011
“Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms”
PDF Read More →

Thomas et al; AACR 2011 Poster, April 2011
“Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model”
PDF Read More →

He et al; AACR 2010 Poster, April 2010
“Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential”
PDF Read More →



Preclinical Programs

Alvarado et al; SITC 2020 Poster, November 2020
"An Axl-targeting Monoclonal Antibody that Inhibits Axl Activity and Potently Stimulates the Innate Immune Response"
PDF Read More →

Alvarado et al; AACR 2019 Poster, April 2019
"Monoclonal antibodies targeting the TAM family of receptor tyrosine kinases"
 Read More →

Alvarado et al; SITC 2018 Poster, November 2018
"Monoclonal Antibodies Targeting the MerTK Receptor De-repress the Innate Immune Response"
 Read More →

LaVallee et al; Critical Reviews in Oncogenesis, 2015
"Emerging Receptor Tyrosine Kinase Drug Targets: Implications for Antibody-Based Therapies for Oncology and Immunologic Disorders"
 Read More →

 

Vitale et al; AACR 2021 Poster, April 2021
"Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies"
PDF Read More →